Bexotegrast

DB16515InvestigationalSmall molecule

PLN-74809 is a small-molecule that dually inhibits both αvβ6 and αvβ1 to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) . The compound was granted orphan drug... The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical development of...

Primary indication: Through dual inhibition of integrins αvβ6 and αvβ1, PLN-74809 reduces subsequent activation of TGF-β1, which is actively involved in the growth of fibrotic tissue in lung and bile ducts.Curator reviewed
Formula / weight: C₂₇H₃₆N₆O₃ · 492.624 g/mol (avg)
Also known as: (2S)-4-(2-METHOXYETHYL-(4-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)BUTYL)AMINO)-2-(QUINAZOLIN-4-YLAMINO)BUTANOIC ACID · (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid · Butanoic acid, 4-[(2-methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(4-quinazolinylamino)-, (2S)-
Code names: PLN-74809

Resolves to

Compound

UNIIQCV154PFT4CAS2376257-44-0ChEMBLCHEMBL5095257

Structure

InChIKeyCWOFQJBATWQSHL-DEOSSOPVSA-NSMILESCOCCN(CCCCC1=NC2=C(CCCN2)C=C1)CC[C@H](NC1=NC=NC2=C1C=CC=C2)C(O)=O

Targets

P06756ITGAVP05556ITGB1P18564ITGB6

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bexotegrast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account